|
Gastroenterology / Original Article
Impact of hepatitis B virus infection on the risk of gallbladder polyps: a cohort study
Nam Hee Kim, Hong Joo Kim, Ji Hun Kang
Korean J Intern Med. 2023;38(6):844-853. Published online October 18, 2023
Background/Aims: We aimed to determine whether hepatitis B virus (HBV) or hepatitis C virus (HCV) infection remains an important risk factor for gallbladder polyps (GBPs) in the current context of reduced prevalence of these infections.
Methods: The cohort included 392,913 asymptomatic adults who unde..
|
|
|
Gastroenterology / Original Article
The diagnostic significance of hepatitis C virus antibody levels for chronic hepatitis C virus infection
Jin Gu Kang, Myoung Kuk Jang, Jung Hee Kim, Jang Han Jung, Ji Won Park, Sung Eun Kim, Sang Hoon Park, Myung Seok Lee, Ki Tae Suk, Dong Joon Kim, Hyoung Su Kim
Korean J Intern Med. 2023;38(3):362-371. Published online April 11, 2023
Background/Aims: Although anti-hepatitis C virus (HCV) assay is widely used to screen for HCV infection, it has a high false-positive (FP) rate in low-risk populations. We investigated the accuracy of anti-HCV signal-to-cutoff (S/CO) ratio to distinguish true-positive (TP) from FP HCV infection.
Me..
|
|
|
Gastroenterology / Original Article
Comorbidities and the use of comedications among patients with chronic hepatitis C in Korea: A nationwide cross-sectional study
Kyung Min Kwon, Jae-Jun Shim, Gi-Ae Kim, Bo Ok Kim, Helin Han, Hyun Jung Ahn
Korean J Intern Med. 2023;38(3):338-348. Published online April 10, 2023
Background/Aims: Chronic hepatitis C (CHC) is the second leading cause of liver-related mortality and is more prevalent in the elderly population in Korea. Decisions to initiate treatment and selection of proper antiviral agents may be challenging among elderly patients due to relevant comorbidities..
|
|
|
Gastroenterology / Original Article
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo Sung, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Korean J Intern Med. 2022;37(6):1167-1175. Published online May 27, 2022
Background/Aims: To evaluate the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) therapy in hepatitis C virus (HCV)-infected Korean patients in a real clinical setting.
Methods: A total of 273 patients who received LDV/SOF therapy between May 2016 and February 2021 were consecutively enrolle..
|
|
|
Gastroenterology / Original Article
Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease
Ji Eun Ryu, Myeong Jun Song, Seok-Hwan Kim, Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Chul Nam, Hee Yeon Kim, Chang Wook Kim, Hyun Yang, Si Hyun Bae, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Soon Kyu Lee, Pil Soo Sung, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Korean J Intern Med. 2022;37(5):958-968. Published online August 19, 2022
Background/Aims: To evaluate the effectiveness and safety of direct acting antivirals (DAAs) available in chronic kidney disease (CKD) patients with hepatitis C virus (HCV) infection in Korea.
Methods: In a retrospective, multicenter cohort study, 362 patients were enrolled from 2015 to 2019. The e..
|
|
|
Gastroenterology / Original Article
Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study
Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong
Korean J Intern Med. 2021;36(Suppl 1):S1-S8. Published online June 17, 2020
Background/Aim: This study aimed to establish the real-world effectiveness and safety of grazoprevir/elbasvir (EBR/GZR) therapy in South Korea.
Methods: A total of 242 patients with chronic hepatitis C virus (HCV) genotype 1 or 4 infection who started EBR/GZR were consecutively enrolled from seven..
|
|
|
Gastroenterology / Original Article
The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
Sung Yong Han, Hyun Young Woo, Jeong Heo, Sang Gyu Park, Sung Ik Pyeon, Young Joo Park, Dong Uk Kim, Gwang Ha Kim, Hyung Hoi Kim, Geun Am Song, Mong Cho
Korean J Intern Med. 2021;36(3):544-556. Published online March 19, 2019
Background/Aims: Real-world, clinical practice data are lacking about sofosbuvir/ ribavirin (SOF/RBV) treatment of Korean patients with hepatitis C virus genotype 2 (HCV GT2) infection. This study investigated the efficacy and safety of SOF/RBV in Korean patients with HCV GT2 infection and clinical ..
|
|
|
Gastroenterology / Original Article
Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
Byung Soo Kwan, Jeong Han Kim, Seong Jun Park, Won Hyeok Choe, So Young Kwon, Byung-Chul Yoo
Korean J Intern Med. 2021;36(2):292-304. Published online April 3, 2020
Background/Aims: Chronic hepatitis C (CHC) treatment has dramatically improved since direct-acting antiviral (DAA) therapy was introduced. However, the use of DAA therapy in CHC patients with hepatocellular carcinoma (HCC) remains controversial. We investigated the DAA treatment response in CHC pati..
|
|
|
Gastroenterology / Original Article
Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study
Jae Yoon Jeong, Dae Won Jun, Sol Ji Park, Joo Hyun Sohn, Sang Gyune Kim, Se Whan Lee, Soung Won Jeong, Moon Young Kim, Won Kim, Jae-Jun Shim, Hyoung Su Kim, Ki Tae Suk, Sang Bong Ahn
Korean J Intern Med. 2020;35(5):1074-1083. Published online November 12, 2019
Background/Aims: We aimed to assess the role of vitamin D supplementation in the response to pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV) treatment in patients with chronic hepatitis C (CHC).
Methods: Our study was a multi-center, randomized controlled trial in 11 hospitals. CHC patient..
|
|
|
Gastroenterology / Original Article
Prognostic impact of hepatitis B or C on intrahepatic cholangiocarcinoma
Jung Woong Seo, Byung Soo Kwan, Young Koog Cheon, Tae Yoon Lee, Chan Sup Shim, So Young Kwon, Won Hyeok Choe, Byung Chul Yoo, Jeong Min Yoon, Jung Hoon Lee
Korean J Intern Med. 2020;35(3):566-573. Published online January 10, 2020
Background/Aims: Intrahepatic cholangiocarcinoma (ICC) is the second-most common primary liver malignancy, arising from the peripheral intrahepatic bile duct epithelium. Hepatitis B virus (HBV) or hepatitis C virus (HCV) may be involved in the development of ICC. We explored the prognostic value of ..
|
|
|
Gastroenterology / Original Article
Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis
Hee Yeon Seo, Myeong-Sook Seo, Sun-Young Yoon, Jong Wook Choi, Soon Young Ko
Korean J Intern Med. 2020;35(3):559-565. Published online May 10, 2019
Background/Aims: New direct-acting antivirals have shown surprising success in the treatment of hepatitis C, not only in the general population, but also in difficult-to-treat cohorts. However, there is still limited data regarding direct-acting antivirals, including sofosbuvir (SOF), in the context..
|
|
|
Gastroenterology / Original Article
Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C
Baek Gyu Jun, Eui Ju Park, Woong Cheul Lee, Jae Young Jang, Soung Won Jeong, Young Don Kim, Gab Jin Cheon, Young Sin Cho, Sae Hwan Lee, Hong Soo Kim, Yun Nah Lee, Sang Gyune Kim, Young Seok Kim, Boo Sung Kim
Korean J Intern Med. 2019;34(5):989-997. Published online March 14, 2018
Background/Aims: This study was conducted to clarify the sustained virological response (SVR) prediction ability of baseline and treatment-related factors in patients with chronic hepatitis C virus (HCV) infection.
Methods: This retrospective study collected data at four tertiary referral hospitals..
|
|
|
Gastroenterology / Original Article
Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak
Korean J Intern Med. 2019;34(4):794-801. Published online May 25, 2018
Background/Aims: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of DCV and ASV combination therapy for patient..
|
|
|
Nephrology / Review
Hepatitis C virus infection in chronic kidney disease: paradigm shift in management
So Mi Kim, Il Han Song
Korean J Intern Med. 2018;33(4):670-678. Published online June 28, 2018
Hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is associated with increased liver-related morbidity and mortality rates, accelerated progression to end-stage renal disease, and risk of cardiovascular events. CKD patients with HCV infection require antiviral therapy. Pegylated inte..
|
|
|
Letter to the editor
Development of bronchiolitis obliterans organizing pneumonia during standard treatment of
hepatitis C with Peg-IFNα2b
Eun Chung, Kihoon Park, Jo Heon Kim, Nam Ik Han, Young Sok Lee, Si Hyun Bae, Chung-Hwa Park
Korean J Intern Med. 2017;32(6):1098-1100. Published online August 21, 2017
|
|
|
Gastroenterology / Original Article
Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection
In Soo Oh, Joung Won Won, Hyung Joon Kim, Hyun Woong Lee
Korean J Intern Med. 2017;32(6):1010-1017. Published online August 11, 2017
Background/Aims: Combined treatment of pegylated interferon-α (PEG-IFN) and ribavirin (RBV) has long been accepted as the standard treatment for chronic hepatitis C virus (HCV) infection. Many predictive factors for treatment response have been identified. The aim of this study was to evaluate the..
|
|
|
Infectious diseases / Original Article
Incidence and risk factors of hepatitis C virus infection among human immunodeficiency virus
(HIV) patients in a large HIV clinic in South Korea
Shinwon Lee, Sun Hee Lee, Su Jin Lee, Kye-Hyung Kim, Jeong Eun Lee, Heerim Cho, Seung Geun Lee, Joo Seop Chung, Ihm Soo Kwak
Korean J Intern Med. 2016;31(4):772-778. Published online April 27, 2016
Background/Aims: Increasing incidences of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected men who have sex were reported in the United States and Europe. However, few studies regarding the epidemiology of HCV infection in HIV-infected patients in Asian countries have..
|
|
|
Gastroenterology / Original Article
Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C
Yong Hwang, Won Kim, So Young Kwon, Hyung Min Yu, Jeong Han Kim, Won Hyeok Choe
Korean J Intern Med. 2015;30(6):792-800. Published online October 30, 2015
Background/Aims: Thyroid dysfunction (TD) is more likely to occur in patients with chronic hepatitis C (CHC) and is particularly associated with interferon (IFN) treatment. The purpose of this study was to investigate the incidence, outcomes, and risk factors for TD during pegylated interferon (PEG-..
|
|
|
Gastroenterology / Review
A 2015 roadmap for the management of hepatitis C virus infections in Asia
Seng Gee Lim, Yock Young Dan
Korean J Intern Med. 2015;30(4):423-433. Published online June 29, 2015
The prevalence of hepatitis C virus (HCV) in Asia is 0.5% to 4.7%, with three different genotypes predominating, depending on the geographic region: genotype 1b in East Asia, genotype 3 in South and Southeast Asia, and genotype 6 in Indochina. Official approval for direct-acting antiviral agents (DA..
|
|
|
Case Report
Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin
Tae-Hee Lee, Kee-Ook Lee, Yong-Seok Kim, Sun-Moon Kim, Kyu-Chan Huh, Young-Woo Choi, Young-Woo Kang
Korean J Intern Med. 2014;29(3):370-374. Published online April 29, 2014
Various adverse events have been reported during combination therapy with pegylated (PEG)-interferon-α and ribavirin, although opportunistic infections, especially cryptococcal meningitis, are very rare. A 61-year-old woman complained of headaches and a fever during treatment of a chronic hepatiti..
|
|
|
